Long-term visual outcome and its predictors in macular oedema secondary to retinal vein occlusion treated with dexamethasone implant

Catharina Busch, Matus Rehak, Chintan Sarvariya, Dinah Zur, Matias Iglicki, Luiz H. Lima, Alessandro Invernizzi, Francesco Viola, Kushal Agrawal, Suthasinee Sinawat, Aude Couturier, Aanchal Mehta, Rakesh Juneja, Hardik Jain, Aniruddha Kishandutt Agarwal, Neha Goel, Manish Nagpal, Vishali Gupta, Alay Banker, Anat LoewensteinMali Okada, Ali Osman Saatci, Ahmad M. Mansour, Jay Chhablani

Research output: Contribution to journalArticle

Abstract

Background: To evaluate the functional long-term outcome in patients with macular oedema (MO) secondary to central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) treated with dexamethasone implant (DEX implant) and to identify its clinical predictors. Methods: A 24-month, retrospective, multinational, real-world study. Chart review of patients with either naïve or recurrent MO secondary to CRVO/BRVO treated with DEX implant, including best-corrected visual acuity (BCVA), central subfield thickness (CST), demographic baseline characteristics and details of any additional treatment during follow-up. Results: A total of 155 eyes (65 CRVO, 90 BRVO) from 155 patients were included. At 24 months, mean BCVA did not change significantly in CRVO ('2.1±24.5 letters, p=0.96) and BRVO patients (1.3±27.0 letters, p=0.07). A worse baseline BCVA (p<0.001), visual acuity (VA) gain ≥5 letters at 2 months (p=0.006) and no need for adjunctive intravitreal therapy after first DEX implant (p=0.001) were associated with a better final BCVA gain. Treatment-naïve patients (p=0.006, OR: 0.25, 95% CI 0.11 to 0.57) and those with a baseline CST≤400 μm (p=0.02, OR: 0.25, 95% CI 0.10 to 0.63) were identified as being less likely to need additional intravitreal therapy. Conclusion: Clinical baseline characteristics and the early treatment response were identified as possible predictors for long-term outcome and the need of adjunctive intravitreal therapy in MO secondary to BRVO/CRVO treated by DEX implant.

Original languageEnglish
Pages (from-to)463-468
JournalBritish Journal of Ophthalmology
Volume103
Issue number4
DOIs
Publication statusPublished - 2019

Fingerprint

Retinal Vein Occlusion
Macular Edema
Dexamethasone
Retinal Vein
Visual Acuity
Therapeutics
Demography

Keywords

  • Long-term outcome

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Long-term visual outcome and its predictors in macular oedema secondary to retinal vein occlusion treated with dexamethasone implant. / Busch, Catharina; Rehak, Matus; Sarvariya, Chintan; Zur, Dinah; Iglicki, Matias; Lima, Luiz H.; Invernizzi, Alessandro; Viola, Francesco; Agrawal, Kushal; Sinawat, Suthasinee; Couturier, Aude; Mehta, Aanchal; Juneja, Rakesh; Jain, Hardik; Agarwal, Aniruddha Kishandutt; Goel, Neha; Nagpal, Manish; Gupta, Vishali; Banker, Alay; Loewenstein, Anat; Okada, Mali; Saatci, Ali Osman; Mansour, Ahmad M.; Chhablani, Jay.

In: British Journal of Ophthalmology, Vol. 103, No. 4, 2019, p. 463-468.

Research output: Contribution to journalArticle

Busch, C, Rehak, M, Sarvariya, C, Zur, D, Iglicki, M, Lima, LH, Invernizzi, A, Viola, F, Agrawal, K, Sinawat, S, Couturier, A, Mehta, A, Juneja, R, Jain, H, Agarwal, AK, Goel, N, Nagpal, M, Gupta, V, Banker, A, Loewenstein, A, Okada, M, Saatci, AO, Mansour, AM & Chhablani, J 2019, 'Long-term visual outcome and its predictors in macular oedema secondary to retinal vein occlusion treated with dexamethasone implant', British Journal of Ophthalmology, vol. 103, no. 4, pp. 463-468. https://doi.org/10.1136/bjophthalmol-2017-311805
Busch, Catharina ; Rehak, Matus ; Sarvariya, Chintan ; Zur, Dinah ; Iglicki, Matias ; Lima, Luiz H. ; Invernizzi, Alessandro ; Viola, Francesco ; Agrawal, Kushal ; Sinawat, Suthasinee ; Couturier, Aude ; Mehta, Aanchal ; Juneja, Rakesh ; Jain, Hardik ; Agarwal, Aniruddha Kishandutt ; Goel, Neha ; Nagpal, Manish ; Gupta, Vishali ; Banker, Alay ; Loewenstein, Anat ; Okada, Mali ; Saatci, Ali Osman ; Mansour, Ahmad M. ; Chhablani, Jay. / Long-term visual outcome and its predictors in macular oedema secondary to retinal vein occlusion treated with dexamethasone implant. In: British Journal of Ophthalmology. 2019 ; Vol. 103, No. 4. pp. 463-468.
@article{5c04544c77da4554b225461ba1a3b280,
title = "Long-term visual outcome and its predictors in macular oedema secondary to retinal vein occlusion treated with dexamethasone implant",
abstract = "Background: To evaluate the functional long-term outcome in patients with macular oedema (MO) secondary to central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) treated with dexamethasone implant (DEX implant) and to identify its clinical predictors. Methods: A 24-month, retrospective, multinational, real-world study. Chart review of patients with either na{\"i}ve or recurrent MO secondary to CRVO/BRVO treated with DEX implant, including best-corrected visual acuity (BCVA), central subfield thickness (CST), demographic baseline characteristics and details of any additional treatment during follow-up. Results: A total of 155 eyes (65 CRVO, 90 BRVO) from 155 patients were included. At 24 months, mean BCVA did not change significantly in CRVO ('2.1±24.5 letters, p=0.96) and BRVO patients (1.3±27.0 letters, p=0.07). A worse baseline BCVA (p<0.001), visual acuity (VA) gain ≥5 letters at 2 months (p=0.006) and no need for adjunctive intravitreal therapy after first DEX implant (p=0.001) were associated with a better final BCVA gain. Treatment-na{\"i}ve patients (p=0.006, OR: 0.25, 95{\%} CI 0.11 to 0.57) and those with a baseline CST≤400 μm (p=0.02, OR: 0.25, 95{\%} CI 0.10 to 0.63) were identified as being less likely to need additional intravitreal therapy. Conclusion: Clinical baseline characteristics and the early treatment response were identified as possible predictors for long-term outcome and the need of adjunctive intravitreal therapy in MO secondary to BRVO/CRVO treated by DEX implant.",
keywords = "Long-term outcome",
author = "Catharina Busch and Matus Rehak and Chintan Sarvariya and Dinah Zur and Matias Iglicki and Lima, {Luiz H.} and Alessandro Invernizzi and Francesco Viola and Kushal Agrawal and Suthasinee Sinawat and Aude Couturier and Aanchal Mehta and Rakesh Juneja and Hardik Jain and Agarwal, {Aniruddha Kishandutt} and Neha Goel and Manish Nagpal and Vishali Gupta and Alay Banker and Anat Loewenstein and Mali Okada and Saatci, {Ali Osman} and Mansour, {Ahmad M.} and Jay Chhablani",
year = "2019",
doi = "10.1136/bjophthalmol-2017-311805",
language = "English",
volume = "103",
pages = "463--468",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "4",

}

TY - JOUR

T1 - Long-term visual outcome and its predictors in macular oedema secondary to retinal vein occlusion treated with dexamethasone implant

AU - Busch, Catharina

AU - Rehak, Matus

AU - Sarvariya, Chintan

AU - Zur, Dinah

AU - Iglicki, Matias

AU - Lima, Luiz H.

AU - Invernizzi, Alessandro

AU - Viola, Francesco

AU - Agrawal, Kushal

AU - Sinawat, Suthasinee

AU - Couturier, Aude

AU - Mehta, Aanchal

AU - Juneja, Rakesh

AU - Jain, Hardik

AU - Agarwal, Aniruddha Kishandutt

AU - Goel, Neha

AU - Nagpal, Manish

AU - Gupta, Vishali

AU - Banker, Alay

AU - Loewenstein, Anat

AU - Okada, Mali

AU - Saatci, Ali Osman

AU - Mansour, Ahmad M.

AU - Chhablani, Jay

PY - 2019

Y1 - 2019

N2 - Background: To evaluate the functional long-term outcome in patients with macular oedema (MO) secondary to central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) treated with dexamethasone implant (DEX implant) and to identify its clinical predictors. Methods: A 24-month, retrospective, multinational, real-world study. Chart review of patients with either naïve or recurrent MO secondary to CRVO/BRVO treated with DEX implant, including best-corrected visual acuity (BCVA), central subfield thickness (CST), demographic baseline characteristics and details of any additional treatment during follow-up. Results: A total of 155 eyes (65 CRVO, 90 BRVO) from 155 patients were included. At 24 months, mean BCVA did not change significantly in CRVO ('2.1±24.5 letters, p=0.96) and BRVO patients (1.3±27.0 letters, p=0.07). A worse baseline BCVA (p<0.001), visual acuity (VA) gain ≥5 letters at 2 months (p=0.006) and no need for adjunctive intravitreal therapy after first DEX implant (p=0.001) were associated with a better final BCVA gain. Treatment-naïve patients (p=0.006, OR: 0.25, 95% CI 0.11 to 0.57) and those with a baseline CST≤400 μm (p=0.02, OR: 0.25, 95% CI 0.10 to 0.63) were identified as being less likely to need additional intravitreal therapy. Conclusion: Clinical baseline characteristics and the early treatment response were identified as possible predictors for long-term outcome and the need of adjunctive intravitreal therapy in MO secondary to BRVO/CRVO treated by DEX implant.

AB - Background: To evaluate the functional long-term outcome in patients with macular oedema (MO) secondary to central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) treated with dexamethasone implant (DEX implant) and to identify its clinical predictors. Methods: A 24-month, retrospective, multinational, real-world study. Chart review of patients with either naïve or recurrent MO secondary to CRVO/BRVO treated with DEX implant, including best-corrected visual acuity (BCVA), central subfield thickness (CST), demographic baseline characteristics and details of any additional treatment during follow-up. Results: A total of 155 eyes (65 CRVO, 90 BRVO) from 155 patients were included. At 24 months, mean BCVA did not change significantly in CRVO ('2.1±24.5 letters, p=0.96) and BRVO patients (1.3±27.0 letters, p=0.07). A worse baseline BCVA (p<0.001), visual acuity (VA) gain ≥5 letters at 2 months (p=0.006) and no need for adjunctive intravitreal therapy after first DEX implant (p=0.001) were associated with a better final BCVA gain. Treatment-naïve patients (p=0.006, OR: 0.25, 95% CI 0.11 to 0.57) and those with a baseline CST≤400 μm (p=0.02, OR: 0.25, 95% CI 0.10 to 0.63) were identified as being less likely to need additional intravitreal therapy. Conclusion: Clinical baseline characteristics and the early treatment response were identified as possible predictors for long-term outcome and the need of adjunctive intravitreal therapy in MO secondary to BRVO/CRVO treated by DEX implant.

KW - Long-term outcome

UR - http://www.scopus.com/inward/record.url?scp=85048411779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048411779&partnerID=8YFLogxK

U2 - 10.1136/bjophthalmol-2017-311805

DO - 10.1136/bjophthalmol-2017-311805

M3 - Article

AN - SCOPUS:85048411779

VL - 103

SP - 463

EP - 468

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 4

ER -